In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Active Implants LLC

www.activeimplants.com

Latest From Active Implants LLC

Active Implants Plans 2019 Commercial Release For NUsurface Meniscus Implant

Active Implants announced the completion of patient enrollment in the VENUS randomized trial of the NUsurface meniscus implant for the treatment of persistent knee pain caused by injured or deteriorated meniscus tissue. Results of the VENUS and SUN trial, which has also completed enrollment, will support a de novo clearance from US FDA, which would make it the first artificial meniscus approved in the US. NUsurface already has a CE mark and the company is planning to start a limited commercial release outside the US in 2019.

Clinical Trials Orthopedics

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017

Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.

Medical Device In Vitro Diagnostics

Execs On The Move, April 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Orthonika: Total Meniscus Replacement

Orthonika Ltd., a spin-out from Imperial College London, is developing TMR, which it describes as the first total knee meniscus replacement. The start-up's implant is based on a proprietary polymer substrate that mimics the structure and function of the healthy meniscus, and the attachment mechanisms to the bone.

Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Active Implants Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Active Implants LLC
  • Senior Management
  • Ted David, Pres. & CEO
    J. Michael Keenan, VP, Admin. & CFO
    Eran Linder-Ganz, PhD, VP, R&D
    Adam Klyce, VP, Mktg.
  • Contact Info
  • Active Implants LLC
    Phone: (901) 762-0352
    5865 Ridgeway Center Pkwy.
    Ste. 218
    Memphis, TN 38120
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register